Orsight Pharma
Neovascular Age-Related Macular Degeneration Drug Treatment
Company Overview
Snapshot
Founded in October 2023 by Mariana Truman, Orsight Pharma operates with 1–10 employees. The company has raised $2.1M across two funding rounds. In May 2024, Orsight Pharma secured a grant from the Israel Innovation Authority.
Business overview
Orsight Pharma is a Health Tech & Life Sciences company focused on developing a breakthrough small molecule treatment for Neovascular Age-Related Macular Degeneration. Its core technology aims to preserve vision and prevent blindness through a novel VEGF-independent mechanism, offering a solution for patients unresponsive to existing therapies and potentially enhancing outcomes when used in combination with current treatments. The company operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, serving the B2C market.
Log in to access full profile ›Company Intelligence Q&A
- What is Orsight Pharma's primary focus?
- Orsight Pharma is developing a small molecule treatment for Neovascular Age-Related Macular Degeneration, aiming to preserve vision and prevent blindness through a novel VEGF-independent mechanism.
- When was Orsight Pharma founded?
- Orsight Pharma was founded in October 2023.
- Who is a co-founder of Orsight Pharma?
- Mariana Truman is a co-founder and CTO of Orsight Pharma.
- Has Orsight Pharma received any grants?
- In May 2024, Orsight Pharma secured a grant from the Israel Innovation Authority.
- Which investor participated in Orsight Pharma's funding rounds?
- NGT HealthCare II participated in a funding round for Orsight Pharma in January 2023.